You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Baxter
AstraZeneca
Mallinckrodt
Merck

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AZD3293

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for AZD3293?

AZD3293 is an investigational drug.

There have been 15 clinical trials for AZD3293. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2016.

The most common disease conditions in clinical trials are Alzheimer Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are AstraZeneca, Eli Lilly and Company, and Parexel.

There are twenty-three US patents protecting this investigational drug and two hundred and nineteen international patents.

Recent Clinical Trials for AZD3293
TitleSponsorPhase
A Study of LY3314814 in Early Alzheimer's Disease DementiaAstraZenecaPhase 3
A Study of LY3314814 in Early Alzheimer's Disease DementiaEli Lilly and CompanyPhase 3
A Study of LY3314814 in Healthy Participants When Taken With RosuvastatinAstraZenecaPhase 1

See all AZD3293 clinical trials

Clinical Trial Summary for AZD3293

Top disease conditions for AZD3293
Top clinical trial sponsors for AZD3293

See all AZD3293 clinical trials

US Patents for AZD3293

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD3293   Get Started for $10 Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder Axovant Sciences GmbH (Basel, CH)   Get Started for $10
AZD3293   Get Started for $10 Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease Axovant Sciences GmbH (Basel, CH)   Get Started for $10
AZD3293   Get Started for $10 Anti-Tau antibodies and methods of use Genentech, Inc. (South San Francisco, CA) AC Immune SA (Lausanne, CH)   Get Started for $10
AZD3293   Get Started for $10 Compounds, compositions and methods Denali Therapeutics Inc. (South San Francisco, CA)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD3293

Drugname Country Document Number Estimated Expiration Related US Patent
AZD3293 Argentina AR104982 2035-06-12   Get Started for $10
AZD3293 Australia AU2016276966 2035-06-12   Get Started for $10
AZD3293 Canada CA2989343 2035-06-12   Get Started for $10
AZD3293 China CN109562085 2035-06-12   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Moodys
AstraZeneca
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.